IFNAR1 and COVID-19: Additionally, given the similar disease outcomes in SARS-CoV-2-infected controls and TLR7-deficient/mutant individuals and responses to anti-IFN/IFNAR antibodies in mice and humans, our results further support the use of a mouse model and mouse-adapted SARS-CoV-2 to study COVID-19 pathogenesis.